Atrial Shunt for Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes from the REDUCE LAP-HF II Trial

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Grant Support/Research Contract - National Institutes of Health; Actelion; AstraZenca; Corvia Medical; Novartis; Pfizer</li><li>Consultant Fee/Honoraria/Speaker's Bureau - Abbott; Actelion; AstraZenca; Amgen; Axon Therapies; Bayer AG; Boehringer Ingelheim; Boston Scientific Corporation; Bristol-Myers Squibb; Cyclerion; Cytokinetics; Edwards Lifesciences; Eidos; Imara; Impluse Dynamics; GSK; Intellia; Ionis; Daiichi-Sankyo/Elil Lilly and Company; Merck/Schering Plough; MyoKardia; Novartis; Novo Nordisk; Pfizer; Prothena; Regeneron; Secretome; Rivus; Sardocor; Adona; Tenax; United Theraputics</li></ul>